10599719

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:53:41 ON 29 JUL 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:53:54 ON 29 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0
DICTIONARY FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10599719x.str





chain nodes :
7 8 9 10 11 13 16
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7 4-16 6-9 7-8 9-10 10-11 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
6-9 7-8 9-10 10-11 11-13
exact bonds :
3-7 4-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:Ph,Cy

G2:CF3,X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 13:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Ph,Cy
G2 CF3,X

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:54:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 136 TO ITERATE

100.0% PROCESSED 136 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2021 TO 3419
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:54:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2734 TO ITERATE

100.0% PROCESSED 2734 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

L3 42 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'HCAPLUS' ENTERED AT 14:54:28 ON 29 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 28 Jul 2008 (20080728/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 2 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:453860 HCAPLUS
DOCUMENT NUMBER: 145:124276
TITLE: Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N→O shift of disubstituted phenyl ring of a bicalutamide derivative
AUTHOR(S): Patil, Renukadevi; Li, Wei; Ross, Charles R.; Kraka, Elfi; Cremer, Dieter; Mohler, Michael L.; Dalton, James T.; Miller, Duane D.
CORPORATE SOURCE: Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA
SOURCE: Tetrahedron Letters (2006), 47(23), 3941-3944
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:124276
AB A novel 1,4-N→O migration of a disubstituted Ph ring was observed during N-methylation of a bicalutamide derivative, (2S)-2-(tert-butyldimethylsilanyloxy)-N-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenoxy)-2-methylpropionamide, in the presence of CsF-Celite/acetonitrile and desilylation of (2S)-2-(tert-butyldimethylsilanyloxy)-N-(4-cyano-3-trifluoromethylphenyl)-3-(4-

fluorophenoxy)-2,N-dimethylpropionamide in tetra-n-butylammonium fluoride/THF. Both NMR and X-ray anal. confirmed the structure of the 1,4-N→O disubstituted Ph ring migrated product.

IT 897364-36-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N→O shift of disubstituted Ph ring of a bicalutamide derivative)

RN 897364-36-2 HCAPLUS

CN Propanamide, 2-[4-cyano-3-(trifluoromethyl)phenoxy]-3-(4-fluorophenoxy)-N,2-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1171080 HCAPLUS
DOCUMENT NUMBER: 143:440077
TITLE: Preparation of cyano phenoxy derivatives as androgen receptor modulators
INVENTOR(S): Du, Daniel Yunlong; Hu, Lain-Yen; Lefker, Bruce Allen; Lei, Huangshu John
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102990	A1	20051103	WO 2005-IB1044	20050414

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

MR, NE, SN, TD, TG

CA 2562672	A1	20051103	CA 2005-2562672		20050414
EP 1740533	A1	20070110	EP 2005-718484		20050414
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
BR 2005009980	A	20071016	BR 2005-9980		20050414
JP 2007533726	T	20071122	JP 2007-508998		20050414
MX 2006PA11116	A	20061116	MX 2006-PA11116		20060927
US 20070197642	A1	20070823	US 2006-599719		20061006
PRIORITY APPLN. INFO.:			US 2004-564667P	P	20040422
			WO 2005-IB1044	W	20050414

OTHER SOURCE(S): CASREACT 143:440077; MARPAT 143:440077

GI



I



II

AB Title compds. I [R1 = halo, cyano, alkoxy, etc.; R2 = (un)substituted aryl; A = (un)substituted alkylene] and their pharmaceutically acceptable salts, are prepared and disclosed as androgen receptor modulators. Thus, e.g., II was prepared by coupling of (2R,3R)-2,3-butanediol with 4-fluoro-2-(trifluoromethyl)-benzonitrile. The activity of I was evaluated in a binding assay against hAR using 3H-dihydrotestosterone as a tracer and it was revealed that selected compds. of the invention possessed IC 50 values in the range of 5 up to 967 nM. I as modulator of androgen receptor should prove useful in the treatment of disease such as but not limited to hormone dependent cancers, benign hyperplasia of the prostate and acne. Pharmaceutical compns. comprising I are disclosed.

IT 868597-42-6P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(preparation of cyano phenoxy derivs. as androgen receptor modulators)

RN 868597-42-6 HCAPLUS

CN Benzonitrile, 4-[1-(methoxymethyl)-2-phenoxyethoxy]-2-(trifluoromethyl)-
(CA INDEX NAME)



IT 868597-43-7P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of cyano phenoxy derivs. as androgen receptor modulators)
RN 868597-43-7 HCAPLUS
CN Benzonitrile, 4-[1-(hydroxymethyl)-2-phenoxyethoxy]-2-(trifluoromethyl)-
(CA INDEX NAME)



IT 868597-44-8P 868597-45-9P 868597-46-0P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyano phenoxy derivs. as androgen receptor modulators)
RN 868597-44-8 HCAPLUS
CN Benzonitrile, 4-[(R)-1-(hydroxymethyl)-2-phenoxyethoxy]-2-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 868597-45-9 HCAPLUS
CN Benzonitrile, 4-[(R)-1-(methoxymethyl)-2-phenoxyethoxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 868597-46-0 HCAPLUS
CN Benzonitrile, 4-[(S)-1-(methoxymethyl)-2-phenoxyethoxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 868597-16-4P 868597-17-5P 868597-18-6P
868597-19-7P 868597-20-0P 868597-21-1P
868597-22-2P 868597-23-3P 868597-24-4P
868597-26-6P 868597-27-7P 868597-28-8P
868597-29-9P 868597-30-2P 868597-31-3P
868597-32-4P 868597-33-5P 868597-34-6P
868597-35-7P 868597-36-8P 868597-37-9P
868597-38-0P 868597-39-1P 868597-40-4P
868597-41-5P 868597-54-0P 868597-55-1P
868597-56-2P 868597-57-3P 868597-58-4P
868597-59-5P 868597-60-8P 868597-61-9P
868597-62-0P 868597-63-1P 868597-64-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyano phenoxy derivs. as androgen receptor modulators)

RN 868597-16-4 HCAPLUS

CN Benzonitrile, 4,4'-[[(1S,2S)-1,2-dimethyl-1,2-ethanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-17-5 HCAPLUS

CN Benzonitrile, 4,4'-[[(1R,2R)-1,2-dimethyl-1,2-ethanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-18-6 HCAPLUS
CN Benzonitrile, 4-[[2-[4-cyano-3-(trifluoromethyl)phenoxy]-3-butenyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-19-7 HCAPLUS
CN Benzonitrile, 4-[1-[[4-cyano-3-(trifluoromethyl)phenoxy]methyl]butoxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-20-0 HCAPLUS
CN Benzonitrile, 4,4'-[[1-(methoxymethyl)-1,2-ethanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-21-1 HCAPLUS
CN Benzonitrile, 4,4'-[[1-(ethoxymethyl)-1,2-ethanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-22-2 HCAPLUS
CN Benzonitrile, 4,4'-[[1-[[(1-methylethyl)amino]methyl]-1,2-ethanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-23-3 HCAPLUS
CN Benzonitrile, 4-[[2-[4-cyano-3-(trifluoromethyl)phenoxy]-6-methylheptyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-24-4 HCAPLUS
CN Benzonitrile, 4-[[1-[[4-cyano-3-(trifluoromethyl)phenoxy]methyl]heptyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-26-6 HCAPLUS
CN Benzonitrile, 4,4'-[1,3-propanediylbis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-27-7 HCAPLUS
CN Benzonitrile, 4,4'-[(2-methyl-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-28-8 HCAPLUS
CN Benzonitrile, 4,4'-[(1-methyl-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-29-9 HCAPLUS
CN Benzonitrile, 4,4'-[[(1R)-1-methyl-1,3-propanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-30-2 HCAPLUS
CN Benzonitrile, 4,4'-[[(1S)-1-methyl-1,3-propanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-31-3 HCAPLUS
CN Benzonitrile, 4,4'-[(1,2-dimethyl-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-32-4 HCAPLUS
CN Benzonitrile, 4-[[1-[2-[4-cyano-3-(trifluoromethyl)phenoxy]ethyl]-3-butenyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-33-5 HCAPLUS
CN Benzonitrile, 4,4'-[(1,1-dimethyl-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-34-6 HCAPLUS
CN Benzonitrile, 4-[[3-[4-cyano-3-(trifluoromethyl)phenoxy]-2-ethylhexyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-35-7 HCAPLUS
CN Benzonitrile, 4,4'-[[(1S,3S)-1,3-dimethyl-1,3-propanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-36-8 HCAPLUS
CN Benzonitrile, 4-[[4-[4-cyano-3-(trifluoromethyl)phenoxy]heptyl]oxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-37-9 HCAPLUS
CN Benzonitrile, 4,4'-[(1,4-dimethyl-1,4-butanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-38-0 HCAPLUS
CN Benzonitrile, 4,4'-[[(1S,4S)-1,4-dimethyl-1,4-butanediyl]bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868597-39-1 HCAPLUS
CN Benzonitrile, 4,4'-[1,5-pentanediylbis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-40-4 HCAPLUS
CN Benzonitrile, 4-[1-[4-[4-cyano-3-(trifluoromethyl)phenoxy]butyl]ethoxy]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-41-5 HCAPLUS
CN Benzonitrile, 4,4'-[(3-methyl-1,5-pentanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-54-0 HCAPLUS
CN Benzonitrile, 4,4'-[(2-hydroxy-1,4-butanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-55-1 HCAPLUS
CN Benzonitrile, 4,4'-[(2-cyclohexyl-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-56-2 HCAPLUS
CN Benzonitrile, 4,4'-[(2-chloro-1,3-propanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-57-3 HCAPLUS
CN Benzonitrile, 4,4'-[(2-chloro-4-hydroxy-1,8-octanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-58-4 HCAPLUS
CN Benzonitrile, 4,4'-[1,10-decanediylbis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-59-5 HCAPLUS
CN Benzonitrile, 4,4'-[(2-cyano-6-hydroxy-4-methyl-1,7-heptanediyl)bis(oxy)]bis[2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 868597-60-8 HCAPLUS
CN Benzonitrile, 4-[3-(4-fluoro-3-hydroxyphenoxy)propoxy]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-61-9 HCAPLUS
CN Benzonitrile, 4-[[2-cyano-4-(dimethylamino)-8-phenoxyoctyl]oxy]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-62-0 HCAPLUS
CN Benzonitrile, 4-[2-(4-cyanophenoxy)-2-(dimethylamino)ethoxy]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-63-1 HCAPLUS
CN Benzonitrile, 4-[1-[(cyclopentyloxy)methyl]-3-(4-hydroxyphenoxy)propoxy]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 868597-64-2 HCAPLUS
CN Benzonitrile, 4-[[4-(dimethylamino)-2-methyl-8-phenoxyoctyl]oxy]-2-(trifluoromethyl)- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.97	197.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 14:56:17 ON 29 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0
DICTIONARY FILE UPDATES: 28 JUL 2008 HIGHEST RN 1036756-19-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10599719y.str





```
chain nodes :
7  8  9  10  11  13  16
ring nodes :
1  2  3  4  5  6
chain bonds :
3-7  4-16  6-9  7-8  9-10  10-11  11-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
4-16  6-9  7-8  9-10  10-11  11-13
exact bonds :
3-7
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G1:Ph,Cy

G2:CF3,X

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  13:CLASS  16:CLASS



L5      STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5              STR
```



G1 Ph,Cy
G2 CF3,X

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 14:56:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2627 TO ITERATE

76.1% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 49466 TO 55614
PROJECTED ANSWERS: 3 TO 197

L6 3 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 14:56:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 51384 TO ITERATE

100.0% PROCESSED 51384 ITERATIONS 79 ANSWERS
SEARCH TIME: 00.00.02

L7 79 SEA SSS FUL L5

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 375.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -1.60

FILE 'HCAPLUS' ENTERED AT 14:56:52 ON 29 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 28 Jul 2008 (20080728/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l7
L8          21 L7

=> s l8 and py<=2004
      25089587 PY<=2004
L9          15 L8 AND PY<=2004

=> s l9 and p/dt
       6288490 P/DT
L10         12 L9 AND P/DT

=> s l10 and us/pc
       1820557 US/PC
L11         11 L10 AND US/PC

=> d l11 ibib abs hitstr tot

L11  ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:971853  HCAPLUS
DOCUMENT NUMBER:          140:16850
TITLE:                    Preparation of Homo-camptothecin derivatives for use
                          in the treatment of cancer
INVENTOR(S):              Yang, Li-Xi
PATENT ASSIGNEE(S):       California Pacific Medical Center, USA; St. Mary's
                          Medical Center
SOURCE:                   PCT Int. Appl., 93 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003101406	A1	20031211	WO 2003-US17681		20030603 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003243397	A1	20031219	AU 2003-243397		20030603 <--
US 20040034050	A1	20040219	US 2003-454525		20030603 <--
PRIORITY APPLN. INFO.:			US 2002-385673P	P	20020603
			WO 2003-US17681	W	20030603

OTHER SOURCE(S): MARPAT 140:16850

GI



I

AB C-20 esters of E-homocamptothecin derivs., such as I [R = (CH2)mOR1; R1 = alkyl, substituted or unsubstituted Ph or naphthyl, cycloalkyl, heterocyclyl, heteroaryl, etc.; m = 1 - 10], were prepared for use in pharmaceutical compns. as antitumor agents. Thus, (±)-E-homocamptothecin derivative I (R = CH2OC6H4-4-F) was prepared in 35% yield by O-acylation of (±)-E-homocamptothecin with 4-fluorophenoxyacetic acid using EDCI and DMAP in CHCl3. The prepared E-homocamptothecin derivs. were tested in vitro for their effect on the growth of VM46 cancer cells and were tested in vivo in C3H/HeJ mice bearing MTG-B tumors.

IT 631090-57-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of E-homocamptothecin derivs. for therapeutic use as anti-cancer agents)

RN 631090-57-8 HCAPLUS

CN Acetic acid, 2-(4-cyano-3-fluorophenoxy)-, 5-ethyl-4,5,13,15-tetrahydro-3,15-dioxo-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinolin-5-yl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964312 HCAPLUS
DOCUMENT NUMBER: 138:39105
TITLE: Preparation of phenylpropionic acid and indolylpropionic acid derivatives and salt thereof as dual or triple agonists of peroxisome proliferator-activated receptors (PPAR)
INVENTOR(S): Matsuura, Fumiyoshi; Emori, Eita; Shinoda, Masanobu; Clark, Richard; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Inoue, Takashi; Miyashita, Sadakazu; Hihara, Taro; Harada, Hitoshi; Ohashi, Kaya
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 404 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100812	A1	20021219	WO 2002-JP3866	20020418 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442319	A1	20021219	CA 2002-2442319	20020418 <--
AU 2002251481	A1	20021223	AU 2002-251481	20020418 <--
AU 2002251481	B2	20070809		
EP 1380562	A1	20040114	EP 2002-720489	20020418 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003810	A2	20040301	HU 2003-3810	20020418 <--
CN 1503774	A	20040609	CN 2002-808498	20020418 <--
BR 2002009027	A	20050524	BR 2002-9027	20020418

NZ 539708	A	20050930	NZ 2002-539708		20020418
NZ 528655	A	20051223	NZ 2002-528655		20020418
RU 2316537	C2	20080210	RU 2003-133744		20020418
ZA 2003006895	A	20051003	ZA 2003-6895		20030903
IN 2003MN00841	A	20050429	IN 2003-MN841		20030908
NO 2003004669	A	20031217	NO 2003-4669		20031017 <--
MX 2003PA09565	A	20040212	MX 2003-PA9565		20031017 <--
US 20040102634	A1	20040527	US 2003-472543		20031022 <--
ZA 2005007922	A	20060726	ZA 2005-7922		20050930
PRIORITY APPLN. INFO.:			JP 2001-123346	A	20010420
			JP 2002-36274	A	20020214
			WO 2002-JP3866	W	20020418

OTHER SOURCE(S): MARPAT 138:39105
GI

I

AB Carboxylic acid derivs. represented by general formula (I), salts or esters thereof, or hydrates thereof [wherein R1 = H, HO, halo, CO2H, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl, C1-6 aminoalkoxy, C1-6 aminoalkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 haloalkylthio, C2-12 alkoxyalkyl, C2-12 alkoxyalkoxy, C2-12 alkoxyalkylthio, C3-7 cycloalkyl, C3-7 cycloalkoxy, etc.; L, M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = CO2H; a solid line accompanied by a dotted line represents a single or double bond; X = a single bond, O, N-(un)substituted NHCQ1O, OCQ1NH, CQ1NHO, ONHCQ1, Q2SO2, SO2Q2, etc., wherein [Q1 = O, S; Q2 = O, (un)substituted NH]; Y = 5 to 14-membered aromatic group or C3-7 alicyclic hydrocarbon group optionally having ≥1 heteroatoms and ≥1 substituents; the ring Z = 5 to 14-membered aromatic group optionally having 1-4 substituents and ≥1 heteroatoms wherein a part of the ring is optionally saturated] are prepared These compds. are dual agonists of PPAR α and γ and triple agonists of PPAR α, β(δ), and γ and are useful as ameliorants (improvers) of insulin resistance, hypolipidemics, anti-osteoporosis agents, antiinflammatory agents, immunomodulators, and anticancer agents, and preventives and/or remedies for diabetes, diabetes complications, fragile X syndrome, hyperlipidemia, obesity, and digestive tract (gastrointestinal) diseases. The gastrointestinal diseases include (1) gastrointestinal inflammations such as ulcerative colitis, Crohn's disease, pancreatitis, and gastritis, (2) gastrointestinal proliferative diseases such as gastrointestinal benign tumors, gastrointestinal polyp, familial polyposis syndrome, colon cancer, rectal cancer, and stomach cancer, (3) gastrointestinal ulcers. They are also preventives and/remedies for (1) angina pectoris or myocardial infarction or its after effect of disease (sequelae), (2) senile dementia, and (3) cerebral vascular dementia based on improving energy metabs. Thus, 2,4-dichloroiodobenzene was coupled with Et 2-isopropoxy-3-[3-(2-propynyloxy)phenyl]propanoate in the presence of (Ph3P)4Pd, CuI, and Et3N

in DMF at room temperature for 2 days followed by hydrolysis with a mixture of 5 N aqueous NaOH and MeOH and acidification with 1 N aqueous HCl, 2-isopropoxy-3-[3-[3-(2,4-dichlorophenyl)-2-propynyl]oxyphenyl]propanoic acid (II). II showed EC50 of 0.008, 1.249, and 0.008 nM for increasing the transcription of human PPAR α, β, and γ, resp., in yeast transfected with GAL4-PPAR LBD chimera expression vector.

IT 478922-56-4P 478928-88-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpropionic acid and indolylpropionic derivs. as dual or triple agonists of peroxisome proliferator-activated receptors (PPAR) for preventives and/or remedies for diseases)

RN 478922-56-4 HCAPLUS
CN Benzenepropanoic acid, 3-[3-(4-cyano-3-fluorophenoxy)-2-hydroxypropoxy]-α-(1-methylethoxy)- (CA INDEX NAME)



RN 478928-88-0 HCAPLUS
CN 1H-Indole-3-propanoic acid, 5-[3-(3-chloro-4-cyanophenoxy)-2-hydroxypropoxy]-1-methyl-α-(1-methylethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:153683 HCAPLUS
DOCUMENT NUMBER: 136:200332
TITLE: Preparation of camptothecin derivatives for treating various types of cancer
INVENTOR(S): Yang, Li-Xi; Pan, Xiandao; Wang, Huijuan
PATENT ASSIGNEE(S): California Pacific Medical Center, USA
SOURCE: U.S., 32 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 6350756	B1	20020226	US 2001-797769	20010301	<--
CA 2434747	A1	20020725	CA 2001-2434747	20011220	<--
WO 2002056885	A1	20020725	WO 2001-US50288	20011220	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002243367	A1	20020730	AU 2002-243367	20011220	<--
AU 2002243367	B2	20061005			
EP 1353673	A1	20031022	EP 2001-989260	20011220	<--
EP 1353673	B1	20070418			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004521105	T	20040715	JP 2002-557393	20011220	<--
CN 1553802	A	20041208	CN 2001-822738	20011220	<--
NZ 527078	A	20051223	NZ 2001-527078	20011220	
AT 359786	T	20070515	AT 2001-989260	20011220	
ES 2284716	T3	20071116	ES 2001-989260	20011220	
US 39707	E1	20070626	US 2003-346835	20030116	<--
MX 2003PA06405	A	20041202	MX 2003-PA6405	20030717	<--

PRIORITY APPLN. INFO.:	US 2001-263040P	P	20010118
	US 2001-797769	A	20010301
	WO 2001-US50288	W	20011220

OTHER SOURCE(S): CASREACT 136:200332; MARPAT 136:200332
GI



I



II

AB Camptothecin derivs., such as I [R = R1O(CH2)m; R1 = Ph optionally substituted with one to five substituents such as halo, alkyl, alkoxy, OH, CN, NO2, amino, haloalkyl, haloalkoxy, formyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino; m = 1-10; a fused 2-,3- or 4-ring heterocyclic system; R2-R5 = H, halo, alkyl, alkoxy, OH, CN, NO2, amino, haloalkyl, haloalkoxy, formyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, etc.], were prepared for treating various types of

cancer. Thus, camptothecin ester II was prepared via reaction of 4-fluorophenoxyacetic acid and camptothecin in presence of EDCI and DMAP. The prepared camptothecin derivs. were tested for antitumor activity; eg. 1 nM of II showed 100% survival of HCT116 in vitro efficacy; >150 in vivo toxicity against MTG40; and 18 surviving days after treatment of MTG-B mouse mammary adenocarcinoma in C3H/Hej mice.

IT 401478-65-7P 401478-98-6P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antitumor activity of camptothecin esters)

RN 401478-65-7 HCAPLUS
CN Acetic acid, 2-(4-cyano-3-fluorophenoxy)-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 401478-98-6 HCAPLUS
CN Acetic acid, 2-(2,5-dibromo-4-cyanophenoxy)-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:205649 HCAPLUS
DOCUMENT NUMBER: 132:237556
TITLE: Polarizable amines and polyimides for optical alignment of liquid crystals
INVENTOR(S): Gibbons, Wayne M.; Shannon, Paul J.; Zheng, Hanxing
PATENT ASSIGNEE(S): Elsicon, Inc., USA
SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 859,404.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6043337	A	20000328	US 1998-80883	19980518 <--
US 6084057	A	20000704	US 1997-859404	19970520 <--
JP 2002515067	T	20020521	JP 1998-550556	19980519 <--
US 6451960	B1	20020917	US 2000-498214	20000204 <--
US 6552161	B1	20030422	US 2000-536423	20000328 <--
PRIORITY APPLN. INFO.:			US 1997-859404	A2 19970520
			US 1998-80883	A 19980518
			WO 1998-US10281	W 19980519

GI



I



II

AB A polyamic acid composition which is the reaction product of an amine component and a tetracarboxylic dianhydride component comprises at least one structural element of each of the following formulas I and II, wherein X4 is an electron withdrawing group having a pos. σ, A is a trivalent organic moiety, P is a polar group comprising a π electron system containing at least one heteroatom selected from N, O, and S; and Lf consists essentially of: X(CH2)n(CF2)p(CH2)nX wherein (CF2)p is a straight chain or branched chain perfluoroalkyl radical, p is 4-20, X is CH2O, CH2S,CH2NR, O, S, NR and a covalent bond, wherein R is a C1-4 hydrocarbon, n is up to 4; and M is a tetravalent organic radical derived from the tetracarboxylic dianhydride containing at least two carbon atoms, no more than two carbonyl groups of the dianhydride being attached to any one carbon atom of the tetravalent radical. Polyimides prepared from the polyamic acids can be

used for inducing alignment of a liquid crystal medium with polarized light in liquid crystal display elements.

IT 216691-45-1P 216691-48-4P 216691-49-5P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(monomer; polarizable amines and polyimides for optical alignment of liquid crystals)

RN 216691-45-1 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



RN 216691-48-4 HCAPLUS
CN Benzonitrile, 4-[[10-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorodecyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



RN 216691-49-5 HCAPLUS
CN Benzonitrile, 4-[[8-(2,4-diaminophenoxy)-3,3,4,4,5,5,6,6-octafluorooctyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



IT 216691-44-0P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(polarizable amines and polyimides for optical alignment of liquid crystals)

RN 216691-44-0 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-dinitrophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



IT 216691-79-1DP, perfluoroalkyloxyaniline amide derivs.
216691-80-4P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(polarizable amines and polyimides for optical alignment of liquid crystals)
RN 216691-79-1 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione] and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 2421-28-5
CMF C17 H6 O7



CM 3

CRN 364-13-6
CMF C7 H7 F3 N2



RN 216691-80-4 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione], 3a,4,5,7a-tetrahydro-7-methyl-5-(tetrahydro-2,5-dioxo-3-furanyl)-1,3-isobenzofurandione and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 73003-90-4
CMF C13 H12 O6



CM 3

CRN 2421-28-5
CMF C17 H6 O7



CM 4

CRN 364-13-6
CMF C7 H7 F3 N2



L11 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:622145 HCAPLUS
DOCUMENT NUMBER: 131:221346
TITLE: Process for inducing alignment of liquid crystal medium in liquid-crystal display element
INVENTOR(S): Gibbons, Wayne M.; Shannon, Paul Joseph; Zheng, Hanxing
PATENT ASSIGNEE(S): Elsicon Inc., USA
SOURCE: U.S., 10 pp., Cont.-in-part of U.S. 5,807,498. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5958293	A	19990928	US 1998-80639	19980518	<--
US 5807498	A	19980915	US 1996-624945	19960329	<--
US 5965691	A	19991012	US 1997-886560	19970701	<--
KR 2000005064	A	20000125	KR 1998-707692	19980928	<--
US 6200655	B1	20010313	US 1999-238683	19990125	<--
WO 9960073	A1	19991125	WO 1999-US10752	19990514	<--

W: JP, KR
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

JP 2002515617	T	20020528	JP 2000-549682	19990514	<--
TW 230841	B	20050411	TW 1999-88108108	19990628	
PRIORITY APPLN. INFO.:			US 1996-624945	A2 19960329	
			US 1997-886560	A3 19970701	
			US 1998-80638	A 19980518	
			US 1998-80639	A 19980518	
			WO 1999-US10752	W 19990514	

AB A process for inducing alignment of a liquid crystal adjacent to a surface of an optical alignment layer comprises exposing at least one optical alignment layer to a polarized light, the polarized light having a wavelength within the absorption band of the optical alignment layer, wherein the exposed alignment layer induces alignment of the liquid crystal medium at an angle + and -θ with respect to the direction of the polarization of the incident light beam and along the surface of the optical alignment layer, and applying a liquid crystal medium to the optical alignment layer, wherein the optical alignment layer is a polyimide comprising an amine component having a 2-substituted 1,4-benzenediamine wherein the 2-substituent is an electron withdrawing group having a pos. σ. Also claimed is a liquid-crystal display element made by the process.

IT 243657-46-7P 243657-47-8P
RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation and use in inducing alignment of liquid crystals in liquid-crystal display devices)

RN 243657-46-7 HCAPLUS

CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione], 4-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzenamine and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 142706-76-1
CMF C14 H8 F15 N O



CM 3

CRN 2421-28-5
CMF C17 H6 O7



CM 4

CRN 364-13-6
CMF C7 H7 F3 N2



RN 243657-47-8 HCAPLUS
CN Benzonitrile, 2,5-diamino-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione], 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluorobenzonitrile and 4-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzenamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 142706-76-1
CMF C14 H8 F15 N O



CM 3

CRN 14346-13-5
CMF C7 H7 N3



CM 4

CRN 2421-28-5
CMF C17 H6 O7



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:622144 HCAPLUS
DOCUMENT NUMBER: 131:235860
TITLE: Material for inducing alignment of liquid crystals and liquid crystal optical elements
INVENTOR(S): Gibbons, Wayne M.; Shannon, Paul Joseph; Zheng, Hanxing
PATENT ASSIGNEE(S): Elsicon Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5958292	A	19990928	US 1998-80638	19980518 <--
WO 9960073	A1	19991125	WO 1999-US10752	19990514 <--
W: JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002515617	T	20020528	JP 2000-549682	19990514 <--
TW 230841	B	20050411	TW 1999-88108108	19990628

PRIORITY APPLN. INFO.: US 1998-80638 A 19980518
US 1998-80639 A 19980518
WO 1999-US10752 W 19990514

AB Polyamic acids derived from an amine component comprising 2-cyano-1,4-phenylenediamine and a family of diaryl ketones are claimed. The polyamic acids are useful in formation of polyimides for the optical alignment of liquid crystals for the manufacture of liquid crystal optical elements.

IT 216691-79-1P 243657-47-8P
RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation and use for liquid crystal alignment in display devices)

RN 216691-79-1 HCAPLUS

CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione] and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 2421-28-5
CMF C17 H6 O7



CM 3

CRN 364-13-6
CMF C7 H7 F3 N2



RN 243657-47-8 HCAPLUS
CN Benzonitrile, 2,5-diamino-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione], 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluorobenzonitrile and 4-[(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy]benzenamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 142706-76-1
CMF C14 H8 F15 N O



CM 3

CRN 14346-13-5
CMF C7 H7 N3



CM 4

CRN 2421-28-5
CMF C17 H6 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:790754 HCAPLUS
DOCUMENT NUMBER: 130:45428
TITLE: Polarizable amines and polyimides for optical alignment of liquid crystals
INVENTOR(S): Gibbons, Wayne M.; Shannon, Paul J.; Zheng, Hanxing
PATENT ASSIGNEE(S): Alliant Techsystems Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9853361	A2	19981126	WO 1998-US10281		19980519	<--
WO 9853361	A3	19990514				
W: JP, KR						
US 6084057	A	20000704	US 1997-859404		19970520	<--
JP 2002515067	T	20020521	JP 1998-550556		19980519	<--
US 6451960	B1	20020917	US 2000-498214		20000204	<--
PRIORITY APPLN. INFO.:			US 1997-859404	A	19970520	
			US 1998-80883	A	19980518	
			WO 1998-US10281	W	19980519	

OTHER SOURCE(S): MARPAT 130:45428

AB The present invention relates to amine compns. and the preparation of polyimides. The polyimides can be used for inducing alignment of liquid crystals with polarized light in liquid-crystal display devices.

IT 216691-44-0P
RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and reaction in preparing diamines for preparing polyimides for optical alignment of liquid-crystal display devices)

RN 216691-44-0 HCAPLUS

CN Benzonitrile, 4-[[6-(2,4-dinitrophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



IT 216691-45-1P 216691-48-4P 216691-49-5P
RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and reaction in preparing polyimides for optical alignment of

liquid-crystal display devices)
RN 216691-45-1 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



RN 216691-48-4 HCAPLUS
CN Benzonitrile, 4-[[10-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorodecyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



RN 216691-49-5 HCAPLUS
CN Benzonitrile, 4-[[8-(2,4-diaminophenoxy)-3,3,4,4,5,5,6,6-octafluorooctyl]oxy]-2,3,5,6-tetrafluoro- (CA INDEX NAME)



IT 216691-79-1DP, reaction products with 4-pentadecafluoromethoxyaniline 216691-80-4DP, reaction products with 4-pentadecafluoromethoxyaniline 216691-81-5DP, reaction products with 4-pentadecafluoromethoxyaniline 216691-87-1DP, reaction products with 4-pentadecafluoromethoxyaniline
RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation and use in preparing optical alignment layers for liquid-crystal display devices)
RN 216691-79-1 HCAPLUS

CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione] and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 2421-28-5
CMF C17 H6 O7



CM 3

CRN 364-13-6
CMF C7 H7 F3 N2



RN 216691-80-4 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione], 3a,4,5,7a-tetrahydro-7-methyl-5-

(tetrahydro-2,5-dioxo-3-furanyl)-1,3-isobenzofurandione and
2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 73003-90-4
CMF C13 H12 O6



CM 3

CRN 2421-28-5
CMF C17 H6 O7



CM 4

CRN 364-13-6
CMF C7 H7 F3 N2



RN 216691-81-5 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with bis(4-aminophenyl)methanone, 5,5'-carbonylbis[1,3-isobenzofurandione], 3a,4,5,7a-tetrahydro-7-methyl-5-(tetrahydro-2,5-dioxo-3-furanyl)-1,3-isobenzofurandione and 2-(trifluoromethyl)-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 73003-90-4
CMF C13 H12 O6



CM 3

CRN 2421-28-5
CMF C17 H6 O7



CM 4

CRN 611-98-3
CMF C13 H12 N2 O



CM 5

CRN 364-13-6
CMF C7 H7 F3 N2



RN 216691-87-1 HCAPLUS
CN Benzonitrile, 4-[[6-(2,4-diaminophenoxy)-2,2,3,3,4,4,5,5-octafluorohexyl]oxy]-2,3,5,6-tetrafluoro-, polymer with 5,5'-carbonylbis[1,3-isobenzofurandione] and 2,5-diaminobenzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 216691-45-1
CMF C19 H11 F12 N3 O2



CM 2

CRN 14346-13-5
CMF C7 H7 N3



CM 3

CRN 2421-28-5
CMF C17 H6 O7



L11 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:548487 HCAPLUS
DOCUMENT NUMBER: 129:161553
ORIGINAL REFERENCE NO.: 129:32878h,32879a
TITLE: Preparation of 6-aryloxyalkoxy-3-amino-1,2-benzoisoxazole derivatives as LTB-4 receptor antagonists.
INVENTOR(S): Suh, Hong-Suk; Ryu, Jae-Ha; Han, Yong-Nam; Yoon, Sung-june; Kim, Jong-Woo
PATENT ASSIGNEE(S): Dong Wha Pharm. Ind. Co. Ltd., S. Korea
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833779	A1	19980806	WO 1998-KR23	19980204 <--
W: CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2278190	A1	19980806	CA 1998-2278190	19980204 <--
JP 2000507971	T	20000627	JP 1998-532740	19980204 <--
JP 3191943	B2	20010723		
EP 1019384	A1	20000719	EP 1998-902278	19980204 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
KR 513302	B1	20050831	KR 1998-3138	19980204
US 6150390	A	20001121	US 1999-355195	19990721 <--
PRIORITY APPLN. INFO.:			KR 1997-3356 A	19970204
			WO 1998-KR23 W	19980204

GI



I

AB Title compds. (I; n = 3-5), were prepared Thus, I (n = 4) [prepared via cyclization of N,N-diisopropyl-4-(2-isopropylideneiminooxybenzonitrile-4-yloxybutoxy)-3-methoxybenzamide in EtOH/H2O containing HCl] antagonized LTB-4 with IC50 = 7 nM.

IT 188658-61-9P 188658-62-0P 188658-63-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 6-aryloxyalkoxy-3-amino-1,2-benzoisoxazole derivs. as LTB-4 receptor antagonists)

RN 188658-61-9 HCAPLUS

CN Benzamide, 4-[4-(4-cyano-3-fluorophenoxy)butoxy]-3-methoxy-N,N-bis(1-methylethyl)- (CA INDEX NAME)



RN 188658-62-0 HCAPLUS

CN Benzamide, 4-[3-(4-cyano-3-fluorophenoxy)propoxy]-3-methoxy-N,N-bis(1-methylethyl)- (CA INDEX NAME)



RN 188658-63-1 HCAPLUS
CN Benzamide, 4-[[5-(4-cyano-3-fluorophenoxy)pentyl]oxy]-3-methoxy-N,N-bis(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:277045 HCAPLUS
DOCUMENT NUMBER: 122:46487
ORIGINAL REFERENCE NO.: 122:8729a,8732a
TITLE: CAT-1 inhibitors, their synthesis, pharmaceutical compositions, and methods of use
INVENTOR(S): Guthrie, Robert W.; Mullin, John G., Jr.; Kachensky, David F.; Kierstead, Richard W.; Tilley, Jefferson W.; Heathers, Guy P.; Higgins, Alan J.; Lemahieu, Ronald A.
PATENT ASSIGNEE(S): Hoffman-La Roche Inc., USA
SOURCE: U.S., 85 pp. Cont.-in-part of U.S. Ser. No. 698, 014, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5344843	A	19940906	US 1992-850620	19920313 <--
RU 2059603	C1	19960510	RU 1992-5011784	19920131 <--
EP 512352	A2	19921111	EP 1992-107135	19920427 <--
EP 512352	A3	19930310		

EP 512352	B1	19960327				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE						
AT 136018	T	19960415	AT 1992-107135		19920427	<--
AU 9216003	A	19921112	AU 1992-16003		19920504	<--
AU 653398	B2	19940929				
CA 2068076	A1	19921110	CA 1992-2068076		19920506	<--
ZA 9203279	A	19930127	ZA 1992-3279		19920506	<--
NO 9201840	A	19921110	NO 1992-1840		19920508	<--
HU 63602	A2	19930928	HU 1992-1538		19920508	<--
JP 05279353	A	19931026	JP 1992-143375		19920508	<--
JP 07107060	B	19951115				
RO 109938	B1	19950728	RO 1992-622		19920508	<--
BR 9201769	A	19921229	BR 1992-1769		19920511	<--
PRIORITY APPLN. INFO.:			US 1991-698014	B2	19910509	
			US 1992-850620	A	19920313	

OTHER SOURCE(S): MARPAT 122:46487

GI



I

AB The invention relates to compds. I (R1 = OH; R2, R3 = H, alkyl, aryl, alkoxy, etc.; X, Y together = O, or one is amino and other is H; Z = S, CR2=CR2'; A = bond, O, S, SO, CHCH, etc.; B = bond, O, S, SO, etc.; Q = Ph, cyclohexyl, pyridinyl, etc.; n = 1-6) and their pharmaceutically acceptable salts, and when appropriate, enantiomers, racemates, diastereomers or mixts. thereof or geometric isomer or mixts. thereof, and pharmaceutically acceptable salts thereof. The compds. inhibit carnitine acyltransferase 1 (CAT-1) and are therefore useful in the prevention of injury to ischemic tissue, and can limit infarct size, improve cardiac function and prevent arrhythmias during and following a myocardial infarction. 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-α-oxo-2-thiopheneacetic acid (preparation given) inhibited CAT-1 with an IC50 = 0.05 μM. Tablet and capsule formulations containing 4-[2-(2-naphthyloxy)ethoxy]-α-oxobenzeneacetic acid are presented.

IT 145797-35-9P 145797-46-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and pharmaceutical compns. and use of carnitine acyltransferase inhibitor compds.)

RN 145797-35-9 HCAPLUS

CN Benzonitrile, 2,6-dichloro-4-[2-(2-naphthalenyloxy)ethoxy]- (CA INDEX NAME)



RN 145797-46-2 HCAPLUS
CN Benzonitrile, 2,6-difluoro-4-[2-(2-naphthalenyloxy)ethoxy]- (CA INDEX NAME)



L11 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:557314 HCAPLUS
DOCUMENT NUMBER: 121:157314
ORIGINAL REFERENCE NO.: 121:28473a,28476a
TITLE: Preparation of aromatic hydroxyamidine derivatives and their use as leukotriene receptor antagonists.
INVENTOR(S): Suh, Hongsuk
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 601977	A1	19940615	EP 1993-810841	19931130	<--
EP 601977	B1	19970122			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
US 5455274	A	19951003	US 1992-987856	19921209	<--
JP 06263710	A	19940920	JP 1993-296853	19931126	<--
AT 148103	T	19970215	AT 1993-810841	19931130	<--
ES 2096265	T3	19970301	ES 1993-810841	19931130	<--
IL 107842	A	19980816	IL 1993-107842	19931202	<--
FI 9305452	A	19940610	FI 1993-5452	19931203	<--
AU 9352180	A	19940623	AU 1993-52180	19931203	<--
AU 671683	B2	19960905			
CA 2110838	A1	19940610	CA 1993-2110838	19931207	<--
ZA 9309193	A	19940609	ZA 1993-9193	19931208	<--
NO 9304483	A	19940610	NO 1993-4483	19931208	<--
NO 180300	B	19961216			

NO 180300 C 19970326
HU 65778 A2 19940728 HU 1993-3501 19931208 <--
PRIORITY APPLN. INFO.: US 1992-987856 A 19921209
OTHER SOURCE(S): MARPAT 121:157314
GI



I



II

AB Title compds. I (wherein the C(:NOH)NH2 may be in tautomeric form; R1 = (mono- or disubstituted) amino; X1, X3 = O, S; X2 = divalent aliphatic hydrocarbyl which may be interrupted by an aromatic; R3, R4 = H, halo, F3C, aliphatic hydrocarbyl, HO, ether, ester) or a salt thereof, useful, as selective LTB4 receptor antagonists (no data), are prepared 2-Acetoxy-4-[5-(4-cyanophenoxy)pentyloxy]-N,N-bis(1-methylethyl)benzamide (preparation given) in aqueous EtOH was treated with NaOH and HONH2-HCl and refluxed overnight to give II. A capsule formulation comprising I is given.

IT 157332-64-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of LTB4 receptor antagonists)

RN 157332-64-4 HCAPLUS

CN Benzamide, 4-[[5-(4-cyano-3-fluorophenoxy)pentyl]oxy]-N,N-bis(1-methylethyl)- (CA INDEX NAME)



L11 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:147306 HCAPLUS
DOCUMENT NUMBER: 118:147306
ORIGINAL REFERENCE NO.: 118:25323a,25326a
TITLE: Preparation of α-oxobenzeneacetic acids and

related compounds as antiischemics and antiarrhythmics

INVENTOR(S): Guthrie, Robert William; Heathers, Guy Phillip; Higgins, Alan John; Kachensky, David Francis; Kierstead, Richard Wightmann; LeMahieu, Ronald Andrew; Mullin, John Guilfoyle, Jr.; Tilley, Jefferson Wright

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., AG, Switz.

SOURCE: Eur. Pat. Appl., 166 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 512352	A2	19921111	EP 1992-107135	19920427 <--
EP 512352	A3	19930310		
EP 512352	B1	19960327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
US 5344843	A	19940906	US 1992-850620	19920313 <--

PRIORITY APPLN. INFO.: US 1991-698014 A 19910509
US 1992-850620 A 19920313

OTHER SOURCE(S): MARPAT 118:147306

GI



AB Title compds. I [R1 = OH, OR3, NR4R5; 1 of R4, R5 = H, C1-7 (hydroxy)alkyl and the other = H, OH, C1-7 alkyl, C1-7 alkoxy; R3 = (CH2CH2O)mH, CH2CHOHCH2OH, 2,2-dimethyl-1,3-dioxolan-4-yl, CH2CH2NH2, etc.; m = 1-4; R2, R2' = H, C1-7 alkyl, aryl-C1-7 alkyl, C1-7 alkoxy, OH, NH2, C1-7 alkylamino, cyano, halo, SH, etc.; A = bond, O, NR7, S, SO, SO2, C.tplbond.C, CH:CH, CH2CH, NR8CO, CONR9; R7 = H, C1-7 alkyl, acyl; R8,R9 = H, C1-7 alkyl; n = 0-10; B = bond, groups defined for A, CO, CS, (OCH2CH2)mO, etc.; Z = O, S, CR2:CR2', N:CR2, CR2:N, NR11; R11 = H, C1-7 alkyl; XY = O, S, :NOH, alkoxyimino, alkenyloxyimino, hydrazono, etc., or individually 1 of X and Y = halo and the other = H, halo, C1-7 alkyl, aryl-C1-7 alkyl; other possibilities for X and Y; Q = cycloalkyl, aryl, heterocyclyl; with provisos] were prepared as drugs to prevent injury to ischemic tissue and arrhythmias during and after a myocardial infarction. Thus, Me 4-hydroxy-α-oxobenzeneacetate in DMF containing NaH was O-alkylated by Ph(CH2)3Br and the resultant product was hydrolyzed by NaOH in MeOH to give title compound II. II had IC50 of 0.5 μM against carnitine acyltransferase 1 in mitochondria. Over 200 I were prepared Capsules containing I were also prepared

IT 145797-35-9P 145797-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antiischemics and antiarrhythmics)

RN 145797-35-9 HCAPLUS
CN Benzonitrile, 2,6-dichloro-4-[2-(2-naphthalenyloxy)ethoxy]- (CA INDEX NAME)



RN 145797-46-2 HCAPLUS
CN Benzonitrile, 2,6-difluoro-4-[2-(2-naphthalenyloxy)ethoxy]- (CA INDEX NAME)




```
=> d 19 and androgen
'AND' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'
'ANDROGEN' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS
```

```
IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):d his
'D' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
```

```
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d his

     (FILE 'HOME' ENTERED AT 14:53:41 ON 29 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 14:53:54 ON 29 JUL 2008
L1             STRUCTURE UPLOADED
L2             1 S L1
L3            42 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 14:54:28 ON 29 JUL 2008
L4             2 S L3
```

```
     FILE 'REGISTRY' ENTERED AT 14:56:17 ON 29 JUL 2008
L5              STRUCTURE UPLOADED
L6            3 S L5
L7           79 S L5 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 14:56:52 ON 29 JUL 2008
L8           21 S L7
L9           15 S L8 AND PY<=2004
L10          12 S L9 AND P/DT
L11          11 S L10 AND US/PC

=> s l9 and androgen
         36126 ANDROGEN
         28559 ANDROGENS
         44640 ANDROGEN
                 (ANDROGEN OR ANDROGENS)
L12          0 L9 AND ANDROGEN

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     73.40     449.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -8.80     -10.40

STN INTERNATIONAL LOGOFF AT 14:59:53 ON 29 JUL 2008
```